Barbara O Brien, MD
Neurology · Cordova, TNNPI 1972555696
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 1,236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations.
Across 1,236 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$2K
- Amgen$974
- EMD Serono, Inc.$908
- Teva Pharmaceuticals USA, Inc.$858
- Pfizer$771
- plus $11K from 54 others
Across 92 payments — averaging $15,138 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.3M
- GW Research Limited$29K
- Sanofi US Services Inc.$14K
What the payments were for
- Speaking & faculty fees$1751%
- Food & beverage$18,02897%
- Education$4272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,630 in reported general payments places this provider in the 75th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rebif RebidoseInterferon Beta-1a/Albumin | 20 | $203,099 |
| AustedoDeutetrabenazine | 26 | $137,423 |
| TysabriNatalizumab | 12 | $113,244 |
| BafiertamMonomethyl Fumarate | 12 | $102,506 |
| MayzentSiponimod | 12 | $94,500 |
| CopaxoneGlatiramer Acetate | 15 | $85,942 |
| Teriflunomide | 22 | $40,735 |
| Dalfampridine ErDalfampridine | 19 | $38,950 |
| Nurtec OdtRimegepant Sulfate | 19 | $34,406 |
| UbrelvyUbrogepant | 20 | $20,924 |
| Memantine Hcl ErMemantine Hcl | 130 | $17,709 |
| Lamotrigine ErLamotrigine | 20 | $14,034 |
| Emgality PenGalcanezumab-Gnlm | 13 | $12,977 |
| RytaryCarbidopa/Levodopa | 16 | $11,593 |
| ReyvowLasmiditan Succinate | 11 | $9,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $858 | $223,36541 claims |
| BiogenTysabri | $571 | $113,24412 claims |
| NovartisMayzent | $1,677 | $94,50012 claims |
| PfizerNurtec Odt, Dilantin | $771 | $36,54230 claims |
| AbbVieUbrelvy | $2,313 | $20,92420 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $407 | $13,23229 claims |
| Lilly USA, LLCReyvow | $446 | $9,43911 claims |
| Upsher-smith Laboratories LLCTopiramate | $100 | $1,10568 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 361 neurology providers in Tennessee.
Other neurology in Cordova
- Lee SteinCordova$213K
- Kendrick HendersonCordova$28K
- David PritchardCordova$27K
- Oleksandra DrynCordova$26K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
- Sibyl WrayKnoxville$377K
- Christine HagenAlcoa$371K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.